Ian Bezek on X
@PythiaR I think $SRPT is the undisputed king in this regard, at least over a full career. https://t.co/fOpmysh4yC
NASDAQ
Sarepta Therapeutics, Inc.
SRPT
2 stories
$1.8B Market cap · 2026-10-06
Sarepta Risk and the FDA
Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.
